- Home
- PBFS vs AARD Comparison
PBFS vs AARD Comparison
Compare PBFS & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBFS
- AARD
- Stock Information
- Founded
- PBFS 1889
- AARD 2017
- Country
- PBFS United States
- AARD United States
- Employees
- PBFS N/A
- AARD N/A
- Industry
- PBFS Banks
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- PBFS Finance
- AARD Health Care
- Exchange
- PBFS Nasdaq
- AARD Nasdaq
- Market Cap
- PBFS 302.3M
- AARD 271.1M
- IPO Year
- PBFS N/A
- AARD 2025
- Fundamental
- Price
- PBFS $12.41
- AARD $11.99
- Analyst Decision
- PBFS
- AARD Strong Buy
- Analyst Count
- PBFS 0
- AARD 5
- Target Price
- PBFS N/A
- AARD $33.00
- AVG Volume (30 Days)
- PBFS 24.9K
- AARD 36.0K
- Earning Date
- PBFS 09-24-2025
- AARD 08-18-2025
- Dividend Yield
- PBFS N/A
- AARD N/A
- EPS Growth
- PBFS 50.26
- AARD N/A
- EPS
- PBFS 0.91
- AARD N/A
- Revenue
- PBFS $91,369,000.00
- AARD N/A
- Revenue This Year
- PBFS N/A
- AARD N/A
- Revenue Next Year
- PBFS N/A
- AARD N/A
- P/E Ratio
- PBFS $13.59
- AARD N/A
- Revenue Growth
- PBFS 23.15
- AARD N/A
- 52 Week Low
- PBFS $10.07
- AARD $4.88
- 52 Week High
- PBFS $12.65
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- PBFS 55.69
- AARD N/A
- Support Level
- PBFS $12.30
- AARD N/A
- Resistance Level
- PBFS $12.47
- AARD N/A
- Average True Range (ATR)
- PBFS 0.22
- AARD 0.00
- MACD
- PBFS -0.01
- AARD 0.00
- Stochastic Oscillator
- PBFS 62.50
- AARD 0.00
About PBFS Pioneer Bancorp Inc.
Pioneer Bancorp Inc is involved in providing banking services. These services include Personal services such as Checking, Savings, eBanking Cards, and Business services such as Business Deposit and operating Accounts, Business eBanking, and Business loans. Some of the other services of the company include Government Banking, Wealth Management, Benefits Consulting and Insurance.
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.